N-carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amide: fluorogenic substrate for post-proline cleaving enzyme [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 125702 |
| CHEMBL ID | 2159750 |
| SCHEMBL ID | 740254 |
| MeSH ID | M0075380 |
| Synonym |
|---|
| z-gly-pro-amc |
| 68542-93-8 |
| n-carbobenzoxyglycylprolyl-4-methylcoumarinyl amide |
| glycyl-l-proline 4-methyl-coumaryl-7-amide |
| benzyl n-[2-[(2s)-2-[(4-methyl-2-oxochromen-7-yl)carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]carbamate |
| benzyl n-[2-[(2s)-2-[(4-methyl-2-oxo-chromen-7-yl)carbamoyl]pyrrolidin-1-yl]-2-oxo-ethyl]carbamate |
| CHEMBL2159750 |
| z-gly-propmecounh |
| z-gly-pro-nh-mec |
| n-carbobenzoxy-gly-pro-4-methylcoumarinyl amide |
| 7-(n-benzyloxycarbonyl-glycyl-prolyl-amido)-4-methylcoumarin |
| l-prolinamide, n-((phenylmethoxy)carbonyl)glycyl-n-(4-methyl-2-oxo-2h-1-benzopyran-7-yl)- |
| n-carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amide |
| SCHEMBL740254 |
| DTXSID40218662 |
| mfcd00038082 |
| (s)-benzyl 2-(2-(4-methyl-2-oxo-2h-chromen-7-ylcarbamoyl)pyrrolidin-1-yl)-2-oxoethylcarbamate |
| benzyl (s)-(2-(2-((4-methyl-2-oxo-2h-chromen-7-yl)carbamoyl)pyrrolidin-1-yl)-2-oxoethyl)carbamate |
| YWOXKKRKNGWXEG-FQEVSTJZSA-N |
| MS-28526 |
| CS-0610150 |
| HY-D1670 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Prolyl endopeptidase | Homo sapiens (human) | Km | 7.7600 | 6.7000 | 7.7600 | 8.5000 | AID694337; AID694338; AID694339; AID694340; AID694341 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID694338 | Activity of POP in human LN229 cell extracts incubated for 30 mins by fluorimetric assay | 2012 | Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14 | Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells. |
| AID694342 | Activity of human recombinant FAPalpha incubated for 30 mins by fluorimetric assay | 2012 | Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14 | Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells. |
| AID694337 | Activity of POP in human LN18 cell extracts incubated for 30 mins by fluorimetric assay | 2012 | Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14 | Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells. |
| AID694339 | Activity of POP in human LNZ308 cell extracts incubated for 30 mins by fluorimetric assay | 2012 | Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14 | Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells. |
| AID694340 | Activity of POP in human HCEC cell extracts incubated for 30 mins by fluorimetric assay | 2012 | Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14 | Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells. |
| AID694341 | Activity of human recombinant POP incubated for 30 mins by fluorimetric assay | 2012 | Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14 | Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.77) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||